EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review

  • ID: 1291528
  • SWOT Analysis
  • December 2016
  • 47 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Alkermes Plc
  • Camurus AB
  • Cerecor Inc
  • Indivior Plc
  • InteKrin Therapeutics Inc
  • Orexo AB
  • MORE
Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the author to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing a treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder (BED), and treatment for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant's first product, NARCAN Nasal Spray, is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Nov 10, 2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors
Oct 31, 2016: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Jun 09, 2016: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2016 Financial Results and Provides Corporate Update
May 12, 2016: Opiant Pharmaceuticals Announces Appointments Of Gabrielle A. Silver, M.D., And Ann Macdougall To Board Of Directors
Mar 16, 2016: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alkermes Plc
  • Camurus AB
  • Cerecor Inc
  • Indivior Plc
  • InteKrin Therapeutics Inc
  • Orexo AB
  • MORE
List of Tables

List of Figures

Section 1 - About the Company

Opiant Pharmaceuticals Inc - Key Facts

Opiant Pharmaceuticals Inc - Key Employees

Opiant Pharmaceuticals Inc - Key Employee Biographies

Opiant Pharmaceuticals Inc - Major Products and Services

Opiant Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data

Opiant Pharmaceuticals Inc, Pipeline Products by Therapy Area

Opiant Pharmaceuticals Inc, Pipeline Products by Development Phase

Opiant Pharmaceuticals Inc - History

Opiant Pharmaceuticals Inc - Company Statement

Opiant Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Section 2 - Company Analysis

Opiant Pharmaceuticals Inc - Business Description

Opiant Pharmaceuticals Inc - Corporate Strategy

Opiant Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Opiant Pharmaceuticals Inc - Strengths

Opiant Pharmaceuticals Inc - Weaknesses

Opiant Pharmaceuticals Inc - Opportunities

Opiant Pharmaceuticals Inc - Threats

Opiant Pharmaceuticals Inc - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Opiant Pharmaceuticals Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments

Nov 10, 2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors

Oct 31, 2016: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Jun 09, 2016: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2016 Financial Results and Provides Corporate Update

May 12, 2016: Opiant Pharmaceuticals Announces Appointments Of Gabrielle A. Silver, M.D., And Ann Macdougall To Board Of Directors

Mar 16, 2016: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update

Mar 07, 2016: Opiant Pharmaceuticals Announces Ticker Symbol Change to “OPNT”

Feb 17, 2016: Lightlake Therapeutics Announces Name Change To Opiant Pharmaceuticals

Feb 17, 2016: Lightlake Therapeutics Announces Name Change To Opiant Pharmaceuticals

Feb 17, 2016: Opiant Pharmaceuticals Convenes Medical Advisory Board To Support Development Of Pharmacological Treatments For Substance Use, Addictive And Eating Disorders

Feb 16, 2016: Lightlake Therapeutics Expands Drug Development Capabilities by Appointing Mark Ellison, Ph.D., as Executive Vice President Development, Manufacturing and Quality

Section 6 - Appendix

Methodology

Ratio Definitions

About the Author

Contact Us

Disclaimer

List of Tables

Opiant Pharmaceuticals Inc, Key Facts

Opiant Pharmaceuticals Inc, Key Employees

Opiant Pharmaceuticals Inc, Key Employee Biographies

Opiant Pharmaceuticals Inc, Major Products and Services

Opiant Pharmaceuticals Inc, Number of Pipeline Products by Therapy Area

Opiant Pharmaceuticals Inc, Number of Pipeline Products by Development Stage

Opiant Pharmaceuticals Inc, Pipeline Products By Therapy Area and Development Phase

Opiant Pharmaceuticals Inc, History

Opiant Pharmaceuticals Inc, Key Competitors

Opiant Pharmaceuticals Inc, Ratios based on current share price

Opiant Pharmaceuticals Inc, Annual Ratios

Opiant Pharmaceuticals Inc (Cont...1), Annual Ratios

Opiant Pharmaceuticals Inc, Interim Ratios

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Opiant Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Opiant Pharmaceuticals Inc, Pipeline Products by Therapy Area

Opiant Pharmaceuticals Inc, Pipeline Products by Development Phase

Opiant Pharmaceuticals Inc, Performance Chart (2012 - 2016)

Opiant Pharmaceuticals Inc, Ratio Charts

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Note: Product cover images may vary from those shown
3 of 4
  • Titan Pharmaceuticals Inc
  • Shire Plc
  • Orexo AB
  • InteKrin Therapeutics Inc
  • Indivior Plc
  • Cerecor Inc
  • Camurus AB
  • BioDelivery Sciences International Inc
  • Alkermes Plc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll